Earnings results for Seres Therapeutics (NASDAQ:MCRB)
Seres Therapeutics, Inc. is expected* to report earnings on 05/04/2021 before market open. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.33. The reported EPS for the same quarter last year was $-0.28.
Seres Therapeutics last issued its earnings data on March 1st, 2021. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. The firm earned $17.56 million during the quarter, compared to analyst estimates of $8.78 million. Seres Therapeutics has generated ($1.20) earnings per share over the last year. Seres Therapeutics has confirmed that its next quarterly earnings report will be published on Tuesday, May 4th, 2021. Seres Therapeutics will be holding an earnings conference call on Tuesday, May 4th. Interested parties can register for or listen to the call using this link.
Analyst Opinion on Seres Therapeutics (NASDAQ:MCRB)
7 Wall Street analysts have issued ratings and price targets for Seres Therapeutics in the last 12 months. Their average twelve-month price target is $38.17, predicting that the stock has a possible upside of 83.41%. The high price target for MCRB is $49.00 and the low price target for MCRB is $29.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Seres Therapeutics has received a consensus rating of Buy. The company’s average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $38.17, Seres Therapeutics has a forecasted upside of 83.4% from its current price of $20.81. Seres Therapeutics has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: Seres Therapeutics (NASDAQ:MCRB)
Seres Therapeutics does not currently pay a dividend. Seres Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Seres Therapeutics (NASDAQ:MCRB)
In the past three months, Seres Therapeutics insiders have not sold or bought any company stock. Only 4.80% of the stock of Seres Therapeutics is held by insiders. 94.32% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Seres Therapeutics (NASDAQ:MCRB
Earnings for Seres Therapeutics are expected to grow in the coming year, from ($1.14) to ($0.27) per share. The P/E ratio of Seres Therapeutics is -17.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Seres Therapeutics is -17.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
More latest stories: here